Featured Research

from universities, journals, and other organizations

Combination Antiretroviral Therapy Effective At Reducing HIV Resistance In Mothers And Babies Following Mother-to-child Transmission

Date:
October 28, 2009
Source:
Public Library of Science
Summary:
In a clinical trial investigating mother-to-child HIV transmission in South Africa researchers find that adding two other antiretroviral drugs to single dose nevirapine -- an antiretroviral drug given to women and newborn children during labor and delivery to prevent transmission -- is effective in reducing the drug resistance that nevirapine causes when used by itself.

In a clinical trial investigating mother-to-child HIV transmission in South Africa published this week in PLoS Medicine, Neil Martinson (of the Perinatal HIV Research Unit, Soweto, South Africa) and colleagues find that adding two other antiretroviral drugs to single dose nevirapine -- an antiretroviral drug given to women and newborn children during labor and delivery to prevent transmission -- is effective in reducing the drug resistance that nevirapine causes when used by itself.

Related Articles


Such resistance can compromise later treatment regimens that include the same class of drug as nevirapine. The researchers report that the combination drug regimen -- which involved the addition of a twice-daily dose of zidovudine and lamivudine over several days following a single-dose of nevirapine -- is safe and easy to provide, and effective in reducing subsequent nevirapine resistance in both mothers and those babies that are infec ted despite antiretrovirals.

In a related Perspective, Dara Lehman (of Fred Hutchinson Cancer Research Center, Seattle, Washington) and colleagues, uninvolved with the research, say that assuming that there is not a large amount of lurking resistance not detected by the study, the approach may "strike the right balance of a feasible regimen that minimizes resistance" in resource-poor settings where combination antiretroviral therapy may not be available for longer-term use in pregnancy.

Funding: Boehringer Ingelheim, the developer and manufacturer of nevirapine, funded this trial, designed the study, was involved in data collection, and was responsible for data management and involved in the analysis. The decision to publish and preparation of the manuscript included employees of the sponsor, which gave an assurance that all authors have full access to the trial dataset.

Competing interests: M. Hopley, M. Ekelund, D. B. Hall, and P. Robinson are employed by Boehringer Ingelheim, the sponsor of the study, and D. Mayers was employed by Boehringer Ingelheim at the time of the study.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. McIntyre et al. Efficacy of Short-Course AZT Plus 3TC to Reduce Nevirapine Resistance in the Prevention of Mother-to-Child HIV Transmission: A Randomized Clinical Trial. PLoS Medicine, 2009; 6 (10): e1000172 DOI: 10.1371/journal.pmed.1000172

Cite This Page:

Public Library of Science. "Combination Antiretroviral Therapy Effective At Reducing HIV Resistance In Mothers And Babies Following Mother-to-child Transmission." ScienceDaily. ScienceDaily, 28 October 2009. <www.sciencedaily.com/releases/2009/10/091026220007.htm>.
Public Library of Science. (2009, October 28). Combination Antiretroviral Therapy Effective At Reducing HIV Resistance In Mothers And Babies Following Mother-to-child Transmission. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2009/10/091026220007.htm
Public Library of Science. "Combination Antiretroviral Therapy Effective At Reducing HIV Resistance In Mothers And Babies Following Mother-to-child Transmission." ScienceDaily. www.sciencedaily.com/releases/2009/10/091026220007.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins